Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

The Relative Bioavailability of an ESK-001 Tablet Versus Liquid Formulation, and the Effect of Food or Gastric Acid Reduction on the Pharmacokinetics of ESK-001 in Healthy Participants

This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

Inclusion Criteria:

• Healthy Men and woman age 18-60
• Able to provide written informed consent
• Females can not be pregnant or lactating

Exclusion Criteria:

• Prior exposure to ESK-001
• History of malignancy within the last 10 years
• Positive for HIV, Hepatitis B or C
• History of tuberculosis
• Positive test for alcohol or drugs